Be
th Bosley is president/CEO of Boron Specialties, LLC, which
develops chemicals, materials, and applications that leverage the unique properties of boron helping customers source, stock, us
e an
d safely manage boranes at scale. The company specializes in the commercialization of advanced boron-enabled technologies (including translation of leading-edge innovation from academic and government research) for life science, electronics, energy, and other applications through process development, market development, product safety, and regulatory compliance management.  Beth earned her chemistry degree from UCLA under noted boron scientist & National Medal of Science winner Prof. M. Frederick Hawthorne.

Gillian Bunker is an experienced patent attorney who assists start-ups, established companies, universities and other research institutions in all phases of developing, protecting and commercializing inventions. With over 15 years of practice in utility, design and plant patents, Gillian has handled a variety of technologies, including mechanical devices, medical devices, biotechnology, pharmaceuticals, chemistry and agricultural inventions.

Gillian loves technology and innovation, and works closely with clients and inventors to develop a deep understanding of both their technologies and their business needs. Her advice on patent procurement and protection, technology transfer and strategic planning is grounded in business and scientific realities.

Before law school, Gillian earned a Ph.D. in neuroscience and worked as a researcher. Her experience as a scientist helps her partner effectively with researchers and innovators in many disciplines. 


In 2013 Calden Carroll co-founded and became President of SupraSensor Technologies, a University of Oregon spin-out focused on sensors for environmental contaminants. The SupraSensor platform for agricultural monitoring of nitrate was subsequently out-licensed to The Climate Corporation in 2016.

Calden received his Ph.D. in 2011 from the University of Oregon for work on the molecular sensor platform which SupraSensor’s successfully commercialized. As a post-doc, Calden’s  team was awarded the top prize in the National Science Foundation’s Innovation Corps program, designed to take basic research out of the lab and into the private sector. He is a firm believer in the power of investment in the fundamental sciences as a tool to drive revolutionary societal changes, and takes particular pride in developing the nitrate sensor, a technology which can protect the fisheries where he spends so much of his free time today.

Robert Copenhaver  has over 15 years of combined experience in pharmaceutical drug development and pharmaceutical business development. The majority of Rob’s experience in drug development has been in the development of monoclonal antibodies for indications in autoimmunity and oncology. As an industry scientist, Rob helped create 4 different molecules that are in late-stage clinical development. Rob also has extensive experience in business development and licensing, including prior work with biotech consulting firm Campbell Alliance, experience in university tech transfer offices, and as an independent consultant. He is currently Director of Intellectual Property & Business Development at DesignMedix. He holds a Master’s of Science from the University of Texas and an MBA with Honors from the University of Houston.

David H. Farrell, PhD, FAHA, is Founder and Chief Scientific Officer of Gamma Therapeutics, Inc., an Oregon-based early stage biotechnology company developing a novel class of biopharmaceutical and diagnostic test solutions for the cardiovascular disease industry.  He is also a Professor of Surgery at the Oregon Health & Science University, and has appointments in the Department of Molecular and Medical Genetics and the Department of Physiology and Pharmacology.  His academic research interests are in the biochemistry, genetics, regulation, and epidemiology of the blood clotting factor fibrinogen.  Prof. Farrell is currently Chair of the Thrombosis 2 Committee of the American Heart Association and on the Editorial Board of the open access journal Thrombosis.  He has received SBIR/STTR grants from NIH and NSF, as well as a grant from the Office of Naval Research.

Todd French
is an intellectual property attorney serving clients from individuals to global companies securing patent and trademark protection. In prior roles, Todd was an executive in business development, new product research, and patent strategy. Todd holds a Ph.D. in physics and has R&D and patent experience with a range of technologies including chemical entities, pharmaceutical assays, materials, microfluidics, imaging, and data processing.


Paula Hayes is the founder and CEO of Hue Noir, LLC. She is an entrepreneurial cosmetics chemist with a degree in biology, an MBA and a life-long love of makeup. Through Hue Noir, she is sharing her passion for beauty by expertly developing luxury, skin-friendly color cosmetics in a rich palette and premium color effects specifically for women with deeper skin tones. 

Paula began her career as a Research and Development Chemist at American Fruit Processors/Mutual Flavors in Los Angeles, CA. She specialized in new product development for companies in the food, beverage and cosmetics industries.In 2009, Paula founded Hue Noir and began to meticulously build the business from the ground up. Paula graduated from Lewis & Clark College in Portland, OR, where she earned her B.S. in biology and was an all-star track and field athlete. She earned her MBA at the University of Phoenix while working full time as an R&D Chemist. Currently, she is a member of the Board of Trustees at Lewis and Clark College and in 2016 she was appointed by Governor Kate Brown as a Business Commissioner for Oregon Business Development Commission.

Mary P. Hull, Partner, Corporate Practice Group, Stoel Rives LLP, Portland; B.A., cum laude, Amherst College (1993); J.D., magna cum laude, Order of the Coif, Tulane Law School (1997); co-chair of the firm’s Technology Ventures Group; general corporate and securities law practice with an emphasis on representation of emerging-growth companies, and regularly advising start-up and early-stage companies on general corporate governance matters, equity compensation, venture capital and angel financing and mergers and acquisitions; chair, Oregon Entrepreneurs Network (OEN) annual fundraising committee (2015-2017); member, Technology Association of Oregon (TAO) Oregon Technology Awards “Startup” committee (2014); recipient, “Forty Under 40” Award, The Portland Business Journal (2012); listed as an Oregon Super Lawyers Rising Star (2008, 2010-2012); Outstanding Pro Bono Service Award, Lewis & Clark Law School Small Business Legal Clinic (2008-2009); member, OEN nominating committee for Entrepreneurship Awards (2005-2006); member, recruiting committee, OEN Angel Oregon (2006); member AeA emerging business committee (2006); member, Board of Directors of Tucker Maxon School for deaf and hard of hearing children; frequent speaker and author on topics related to her practice.

Leen Kawas is the founder and CEO of M3 Biotechnology. She has led M3 Biotechnology in business and financial growth through two oversubscribed financing rounds. The funds raised will support and accelerate growth of the company and take the lead candidate through the early stages of human testing. In 2016, M3 Biotechnology was named as one of Seattle’s 10 hottest startups by GeekWire in 2016. She also serves on multiple boards, including the Washington Governor’s Life Science Advisory Board and the Scientific Review Board for the Alzheimer’s Drug Discovery Foundation. Dr. Kawas earned a doctorate in molecular pharmacology from Washington State University in 2011. She holds a Doctor of Pharmacy (PharmD.) from the University of Jordan (2008). Dr. Kawas also completed the Executive Training Program at the Foster School of Business, University of Washington (2014).




Robert Masterson‘s cultivation of innovative ideas has led to two life science startups. His entrepreneurial expertise spans product idea generation, development, and commercialization; startup business models and leadership; and presentations and messaging for investors to secure angel and venture capital backing.

Under his leadership as founder, CEO, and CSO of Tessera Diagnostics, the company attracted millions in funding to explore cancer diagnostics (now Onconome, Inc.). In 2006, he co-founded and served as CEO of medical device company Prevencio, Inc., advancing its technology through the development stage.


Damien Munsinger
 
represents and advises employers of all sizes on a wide range of employment matters. As the founder of a successful branding and communications firm, Damien brings a particular understanding of concerns common to all startups and newer employers into his legal practice. An accomplished litigator who thrives in the courtroom, Damien regularly prevents and resolves difficult employment disputes so his clients can focus on what they do best – running and growing their own institutions and businesses.



Kedma Ough
leads innovation for the Oregon Small Business Development Centers (SBDC) and is the Director the SBDC at Mt Hood Community College (MHCC). Under this directive she supports the Inventor Resource Program which includes SBIR/STTR guidance and working with inventors from ideation to commercialization. She has supported clients through product licensing and building product development firms. The Huffington Post has recognized Ough for fueling innovation in Oregon and Inc. Magazine cited Ough for her work in creative financing for minority-owned businesses. Ough is also a contributing writing for Entrepreneur Magazine. She holds a Masters in Business Administration and is a graduate of the LIMA product-licensing program. Locally she has served on the Governors Small Business Advisory council and her past awards have included the SBA’s Women Champion of the Year, Small Business State Champion Award, and National Small Business Influencer Leadership. She calls herself an ‘educated hustler’ and in 2012 managed the National SBIR/STTR Conference which offers the largest seed money for inventors that are developing products for the federal government. As an avid inventor Ough is currently working on a food product concept with her three young boys. She is also a proud fifth generation entrepreneur and her great-great grandfather peddled various products throughout Ireland.


Ethan Perls
jIH6GqRB.jpegtein, founder of Perlara PBC, San Francisco, CA, a biotech startup focused on precision orphan drug discovery. Dr. Perlstein received his Ph.D. in molecular and cell biology from Harvard University, and was a Lewis-Sigler Fellow at Princeton University. He is an author on 19 peer-reviewed scholarly publications, including the discovery of a novel mechanism of action for the antidepressant Zoloft based on studies in yeast cells.





Skip Rung is the President and Executive Director of the Oregon Nanoscience and Microtechnologies Institute. Prior to founding ONAMI in 2003, Skip established an innovation consulting practice in 2001. He was the director of Research and Development at Hewlett-Packard’s (HP) Corvallis facility, which is both the headquarters for HP’s world-leading thermal inkjet printing technology and the company’s most advanced technology R&D and manufacturing site.
Skip has a Bachelor of Science and a Master’s degree in electrical engineering from Stanford University.



Sandra Shotwell is co-founder and CEO of DesignMedix Inc., and co-founder of Elex Biotech LLC, firms that develop small molecule therapeutics for infectious disease and heart disease, respectively.  She is also co-founder of Alta Biomedical Group LLC, a consulting firm focused on commercialization of life science technologies.  A Certified Licensing Professional, she has done biotech and pharmaceutical licensing deals as a Licensing Associate for Stanford University, as founder and Chief of the Technology Licensing Branch for the National Institutes of Health/FDA/CDC, and as Director of Technology Transfer at Oregon Health & Science University. Dr. Shotwell has served on several for-profit and non-profit boards of directors and is an active angel investor.


Andy Soria
is t
he Director of the Berglund Center at Pacific University, an innovation center and small business incubator established in 2014. He has been involved in the development of new products and alternative technologies in energy and materials for over 20 years. He has served at the National Academy of Science–National Research Council as an expert in biofuels, and has worked as a consultant for the International Finance Corporation (The World Bank) and Fortune 500 energy companies. Dr. Soria teaches courses in the broad context of energy, sustainability, environmental science and technology and innovation, and conducts active research in thermochemical conversion of wastes into value added products funded by NSF, USDA and other Federal Agencies.

Prior to academia, he was involved in large-scale geothermal energy, hydropower and oil and gas development across Latin America. Dr. Soria has a Ph.D. in Natural Resources-Wood Chemistry from the University of Idaho.

Jon Summers
is an attorney and CPA who represents technology and emerging growth companies with respect to the formation, financing, governance, and transactional matters. He counsels clients on venture capital and angel financings, mergers and acquisitions, strategic alliances and joint ventures, technology licensing, commercial agreements and general business matters. Jon is experienced in stock option plans, executive compensation, corporate reorganizations and spinouts, securities offerings, and the formation of investment funds. Notable clients include Portland Seed Fund, GlobeSherpa, Giftango (sold to Incomm), Exterro, Sol Republic, Treehouse Island, Nouvola, Schoolhouse Electric, Black Rock Coffee Bar, and Ruby Receptionists. Jon speaks frequently on the subjects of startups, financings, and mergers & acquisitions. Jon teaches an Entrepreneurship seminar at Lewis & Clark Law School. Prior to his legal career, Jon worked for four years for Arthur Andersen & Co., an international public accounting firm, as a financial statement auditor where he earned his certified public accounting license in 1989.

Michael Tippie
brings broad life science expertise to his role as
Entrepreneur-in-Residence at ONAMI, specifically with operations and venture financing. He was instrumental in facilitating acquisitions, public offerings and venture funding at six early-stage companies spanning the therapeutics, diagnostics, life science tools, health care services and medical devices markets. Michael has Bachelor of Science degrees in chemistry from Reed College and the University of Washington, as well as an MBA from the Sloan School at MIT.

Dr. Greg Zafiris
, Alto Law Group LLC Greg Zafiris has been helping clients resolve a wide variety of business issues for over 15 years. He has been general counsel to both private equity and publicly traded companies, giving him experience working in, and not just for, business, as well as strong insight into how best to manage the legal function. His expertise covers intellectual property, licensing, commercial transactions, acquisition and sale of businesses, corporate, and regulatory compliance.